Phase 3 N=3,444 Exacerbation Study
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1). — 1.134; 1.145 Liters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 Midvastus Versus Medial Parapatellar Approach for Minimally Invasive Total Knee Arthroplasty
Osteoarthritis
Primary: Knee Society Score — 98.70; 99.03 score
Phase 3 N=112 A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
Influenza
Primary: Humoral Immune Response in Terms of Hemagglutination Inhibition (HI) Antibodies Against Each of the 4 Vaccine Influenza Strains. — 130.4; 57.3; 404.8; 355.5 Titers
N/A N=290 Neuro-Music-Therapy for Patients With Chronic Tinnitus - a Controlled Clinical Trial
Tinnitus
Primary: Tinnitus Questionnaire (TQ, Goebel and Hiller 1998) Total Score Change From Baseline to End of Treatment — 13.6; 3.7 absolute TF-score change
Phase 4 N=72 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia
Hyperglycemia
Primary: Mean Blood Glucose of All Readings — 157.2; 181.8 mg/dL
Phase 4 N=85 Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™
Intervertebral Disk Degeneration · Intervertebral Disk Displacement · Ossification of Posterior Longitudinal Ligament
Primary: Bone Fusion With CT(Postoperative 6 Months) — 26; 28 participants
Phase 4 N=600 Gatorade/Miralax With or Without Bisacodyl Versus NuLytely for Colonoscopy Preparation
Preparation for Colonoscopy
Primary: The Quality of the Colon Preparation Will be Graded Using the Boston Bowel Preparation Scale — 7.86; 8.05; 7.99 units on a scale
N/A N=12 Repair of Soft Tissue Defect of the Finger Using the Heterodigital Neurocutaneous Island Flap
Sensory Reconstruction of the Volar Aspect of the Finger · The Heterodigital Neurocutaneous Island Flap
Primary: Discriminatory Sensation of the Flap — 8.3 mm
Phase 4 N=72 Management of Superficial Thrombophlebitis
Superficial Thrombophlebitis · Upper Extremity Superficial Thrombophlebitis · Lower Extremity Superficial Thrombophlebitis
Primary: Thrombosis Progression and Venous Thromboembolism (VTE) — 4; 0; 0; 0 participants
Phase 4 N=120 A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers
Influenza, Human
Primary: The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre. — 79.7; 55.9; 86.4; 64.4 percentage of participants
Phase 3 N=477 Comparison of the Safety and Efficacy of Intravenous Iron Versus Oral Iron in the Treatment of Anemia Secondary to Heavy Uterine Bleeding
Anemia
Primary: Number of Subjects Achieving 'Clinical Success'. Clinical Success is Defined as an Increase in Hemoglobin of ≥ 2.0 g/dL — 187; 139 participants
Phase 4 N=77 ISSUE3: International Study on Syncope of Uncertain Etiology 3
Syncope
Primary: Syncope Recurrence Rate — 57; 25 percentage of participants — p=0.04
N/A N=12 Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
Non-Hodgkin's Lymphoma · Lymphoma
Primary: Number of Participants With Complete Response (CR) or Partial Response (PR) — 10; 2 participants
N/A N=47 Measuring Signatures in the Fluid Surrounding the Spinal Cord in Patients Who Have Problems With Intrathecal Drug Delivery
Cerebral Palsy · Multiple Sclerosis · Traumatic Brain Injury
Primary: Classification of Catheter Function by CSF Signatures vs. Physician's Standard Trouble-shooting Diagnosis — 13; 16 Subjects whose CSF data agree with MD Dx
Phase 3 N=28 Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
Blood Coagulation Disorders · Hemophilia A
Primary: Part A - Area Under the Drug Concentration-time Curve (AUC) — 1889.23; 1583.91 Int.units x hours/deciliters (IU*h/dL)